In a study of symptomatic adults tested for SARS-CoV-2 at U.S. pharmacies since Sept. 14, bivalent COVID-19 vaccine boosters provided additional protection compared with previous vaccination with two or more monovalent doses, the Centers for Disease Control and Prevention reported today. The benefit of the bivalent booster increased with time since receipt of the last monovalent dose. 
 
In a separate study released today, adult COVID-19 patients with mild-to-moderate illness who received a prescription for Paxlovid had a 51% lower hospitalization rate than those who did not, CDC said. While the initial clinical trial for Paxlovid preceded the omicron variant’s predominance and included only unvaccinated patients, the new study included people with omicron infection and previous immunity. 

Related News Articles

Headline
Centers for Disease Control and Prevention Director Rochelle Walensky, M.D., today encouraged all eligible Americans to get vaccinated against the flu and…
Headline
The Food and Drug Administration does not currently authorize the monoclonal antibody bamlanivimab for emergency use to treat mild-to-moderate COVID-19 in the…
Headline
The Biden Administration today launched a six-week campaign to encourage Americans to get an updated COVID-19 vaccine. In addition to ongoing pop-up clinics,…
Headline
Children under age 5 are more likely to receive a COVID-19 vaccine if their parents perceive it as safe and their health care provider recommends it, according…
Headline
AHA this week released a new Thanksgiving-focused toolkit to help promote pediatric COVID-19 vaccination on social media, including sample content and graphics…
Headline
The Food and Drug Administration recently updated its health care provider fact sheet on bebtelovimab to note that the monoclonal antibody is not expected…